| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
Form 4: Sawaf Aziz, EVP, Chief Financial Officer
Received 75,000 shares as a grant or award · Granted 150,000 Stock Option (Right to Buy) |
| 16 Nov 2026 |
Form 4: Sabatini Brent, SVP, Chief Accounting Officer
Received 50,000 shares as a grant or award |
| 16 Nov 2026 | 424B5 |
| 12 Nov 2026 | 424B5 |
| 12 Nov 2026 | S-3ASR |
| 10 Nov 2026 | SCHEDULE 13G |
| 09 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Vir Biotechnology, Inc. (the Company) is holding a virtual investor conference call at 5:30 a.m. PT / 8:30 a.m. ET on November 9, 2026, to discuss the topline results from the pivotal Phase 3 ECLIPSE 1 clinical trial evaluating monthly s... |
| 06 Nov 2026 | SCHEDULE 13D/A |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
- Topline data from pivotal Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026 |
| 04 Nov 2026 |
Form 4: de Verneuil Vanina, EVP, General Counsel, Corp Sec
Sold 1,343 shares ($15.2K) · Sold 2,407 shares ($26.7K) |
| 03 Nov 2026 | 144 |
| 02 Nov 2026 | 144 |
| 28 Oct 2026 |
Form 4: Topalian Suzanne Louise, Director
Received 12,731 shares as a grant or award · Granted 25,462 Stock Option (Right to Buy) |
| 28 Oct 2026 |
Form 3: Topalian Suzanne Louise, Director
Holds 0 shares of Common Stock |
| 28 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 26, 2026, the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board fr... |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 14 Oct 2026 |
8-K: Unregistered Sales of Equity Securities; Other Events
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors |
| 08 Oct 2026 |
8-K: Other Events
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer |
| 06 Oct 2026 |
Form 3: Sawaf Aziz, EVP, Chief Financial Officer
Holds 0 shares of Common Stock |
Loading...